August 15, 2017 / 8:35 AM / 2 years ago

BRIEF-Jiangsu Hengrui Medicine passes U.S. FDA approval

Aug 15(Reuters) - Jiangsu Hengrui Medicine Co Ltd :

* Says it received FDA approval for Docetaxel Injection from U.S Food and Drug Administration

* Docetaxel Injection can be used for treatment of mammary cancer, nonsmall-cell lung cancer, prostatic cancer, gastric cancer as well as head and neck SCC

* Company will be able to sell its Docetaxel Injection in the United States after receiving the FDA approval

Source text in Chinese: goo.gl/5Qtw79

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below